Aberdeen Group plc Has $66.85 Million Position in Abivax SA Sponsored ADR $ABVX

Aberdeen Group plc lifted its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 10.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 787,417 shares of the company’s stock after acquiring an additional 76,901 shares during the period. Aberdeen Group plc owned approximately 1.01% of Abivax worth $66,852,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. bought a new stake in Abivax during the third quarter worth $263,000. Envestnet Asset Management Inc. acquired a new position in shares of Abivax during the 3rd quarter worth $1,723,000. Hantz Financial Services Inc. bought a new stake in shares of Abivax during the 3rd quarter worth $52,000. Allianz Asset Management GmbH bought a new stake in shares of Abivax during the 3rd quarter worth $246,000. Finally, Privium Fund Management B.V. acquired a new stake in Abivax in the third quarter valued at about $2,582,000. 47.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on ABVX shares. Oppenheimer set a $131.00 target price on Abivax in a research note on Thursday, January 8th. Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Truist Financial set a $140.00 target price on shares of Abivax in a research report on Monday, November 24th. Wolfe Research raised shares of Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Citigroup reiterated a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $135.08.

Abivax Stock Performance

Shares of Abivax stock opened at $124.99 on Monday. The stock has a market cap of $9.88 billion, a price-to-earnings ratio of -29.90 and a beta of 0.81. Abivax SA Sponsored ADR has a twelve month low of $4.77 and a twelve month high of $148.83. The company’s fifty day moving average is $122.87 and its 200 day moving average is $102.41. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The business had revenue of ($4.92) million during the quarter. Sell-side analysts forecast that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.